-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, the Inner Mongolia Autonomous Region Pharmaceutical Purchasing Center issued the "Notice on Suspension of Qualifications for Drug Transactions such as Weikangling Capsules"
.
The notice shows that according to the "Notice on Matters Concerning Strengthening the Quality and Safety Supervision of Pharmaceutical and Medical Consumables" (Nei Food and Drug Administration [2017] No.
259) and the State Food and Drug Administration website in March 2022, the sampling inspection of drugs in various provinces did not meet the standard requirements.
List, the trading qualifications of 20 drugs in the Inner Mongolia Autonomous Region have been suspended
.
20 drugs were suspended for trading mainly due to differences in traits, quality, loss on drying and other reasons
.
Among them, non-compliance with the "Good Manufacturing Practice for Drugs" accounted for the majority
.
In fact, it is not uncommon for medicines to be suspended from trading.
As far as the Inner Mongolia Autonomous Region is concerned, on January 7 this year, the "Notice on Suspension of Trading Qualifications for Drugs such as Tianma Capsules" (Nei Yao Cai Zhong Zi (2022) No.
2) was issued.
Yichun Wujiashen Pharmaceutical Co.
, Ltd.
has the trading qualifications for 5 drugs including Tianma Capsules produced by Inner Mongolia Autonomous Region
.
It is understood that the above-mentioned drugs whose trading qualifications have been suspended are all from the list of drugs that do not meet the standard requirements for drug sampling in various provinces published on the website of the State Food and Drug Administration in December 2021.
Visible foreign matter, clarity and color of the solution,
etc.
With the continuous tightening of the state's supervision of the pharmaceutical industry, except for Inner Mongolia Autonomous Region, in recent years, it has become very common for medicines in various places to be suspended due to quality and price
.
Since the beginning of this year, a large number of enterprises have been imposed administrative penalties and suspended drug transactions by the provincial drug administrations in many places
.
For example, on March 16, the Shandong Provincial Public Resource Trading Center issued a notice on publicizing the price adjustment of the fifth batch of medicines that were not selected in the centralized procurement by the state
.
After sorting out and publicizing, it can be found that a total of 195 drugs have been adjusted this time, 34 of which are suspended from trading, and 161 are normally on the Internet
.
Among them, the reasons for the suspension of trading include over-evaluation of more than three companies, voluntary withdrawal from the Internet, and the price of over-evaluated drugs is higher than the price of original research drugs
.
Specifically, 2 drugs were suspended from trading due to duplicate products, and 7 drugs were suspended from trading due to over-evaluated drug prices that were higher than the prices of original drugs
.
On January 6, the Guangzhou Public Resource Trading Center issued a notice on suspending the listing of some drugs on the Internet
.
The notice shows that there are 24 varieties of drugs that have been suspended this time, including sodium valproate tablets, flunarizine hydrochloride capsules, Xiangdan injection, nifedipine sustained-release tablets (III), and Tuloteprol paste.
Drugs, Enoxaparin Sodium Injection, Avanafil Tablets, Nifedipine Controlled-Release Tablets and other commonly used drugs, involving 20 pharmaceutical companies
.
In March, the Guangzhou Public Resources Trading Center issued another notice to suspend the listing of some drugs on the Internet
.
This time, a total of 36 batches of drug applications were suspended from the Internet, involving 22 manufacturing companies.
The reasons for the suspension were factors such as the failure of normal production of drugs and the withdrawal of products from the market
.
From the above point of view, China's pharmaceutical industry is at a critical point in its transformation.
After a series of scientific approval, medical insurance fee control, volume procurement, compliance supervision and other policies have hit a combination of punches, the regulatory measures issued by relevant departments are in the process of environmental protection.
In this context, traditional production and marketing models are facing more and more challenges.
For the majority of pharmaceutical companies, compliance will become the basic bottom line of survival in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The notice shows that according to the "Notice on Matters Concerning Strengthening the Quality and Safety Supervision of Pharmaceutical and Medical Consumables" (Nei Food and Drug Administration [2017] No.
259) and the State Food and Drug Administration website in March 2022, the sampling inspection of drugs in various provinces did not meet the standard requirements.
List, the trading qualifications of 20 drugs in the Inner Mongolia Autonomous Region have been suspended
.
20 drugs were suspended for trading mainly due to differences in traits, quality, loss on drying and other reasons
.
Among them, non-compliance with the "Good Manufacturing Practice for Drugs" accounted for the majority
.
In fact, it is not uncommon for medicines to be suspended from trading.
As far as the Inner Mongolia Autonomous Region is concerned, on January 7 this year, the "Notice on Suspension of Trading Qualifications for Drugs such as Tianma Capsules" (Nei Yao Cai Zhong Zi (2022) No.
2) was issued.
Yichun Wujiashen Pharmaceutical Co.
, Ltd.
has the trading qualifications for 5 drugs including Tianma Capsules produced by Inner Mongolia Autonomous Region
.
It is understood that the above-mentioned drugs whose trading qualifications have been suspended are all from the list of drugs that do not meet the standard requirements for drug sampling in various provinces published on the website of the State Food and Drug Administration in December 2021.
Visible foreign matter, clarity and color of the solution,
etc.
With the continuous tightening of the state's supervision of the pharmaceutical industry, except for Inner Mongolia Autonomous Region, in recent years, it has become very common for medicines in various places to be suspended due to quality and price
.
Since the beginning of this year, a large number of enterprises have been imposed administrative penalties and suspended drug transactions by the provincial drug administrations in many places
.
For example, on March 16, the Shandong Provincial Public Resource Trading Center issued a notice on publicizing the price adjustment of the fifth batch of medicines that were not selected in the centralized procurement by the state
.
After sorting out and publicizing, it can be found that a total of 195 drugs have been adjusted this time, 34 of which are suspended from trading, and 161 are normally on the Internet
.
Among them, the reasons for the suspension of trading include over-evaluation of more than three companies, voluntary withdrawal from the Internet, and the price of over-evaluated drugs is higher than the price of original research drugs
.
Specifically, 2 drugs were suspended from trading due to duplicate products, and 7 drugs were suspended from trading due to over-evaluated drug prices that were higher than the prices of original drugs
.
On January 6, the Guangzhou Public Resource Trading Center issued a notice on suspending the listing of some drugs on the Internet
.
The notice shows that there are 24 varieties of drugs that have been suspended this time, including sodium valproate tablets, flunarizine hydrochloride capsules, Xiangdan injection, nifedipine sustained-release tablets (III), and Tuloteprol paste.
Drugs, Enoxaparin Sodium Injection, Avanafil Tablets, Nifedipine Controlled-Release Tablets and other commonly used drugs, involving 20 pharmaceutical companies
.
In March, the Guangzhou Public Resources Trading Center issued another notice to suspend the listing of some drugs on the Internet
.
This time, a total of 36 batches of drug applications were suspended from the Internet, involving 22 manufacturing companies.
The reasons for the suspension were factors such as the failure of normal production of drugs and the withdrawal of products from the market
.
From the above point of view, China's pharmaceutical industry is at a critical point in its transformation.
After a series of scientific approval, medical insurance fee control, volume procurement, compliance supervision and other policies have hit a combination of punches, the regulatory measures issued by relevant departments are in the process of environmental protection.
In this context, traditional production and marketing models are facing more and more challenges.
For the majority of pharmaceutical companies, compliance will become the basic bottom line of survival in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
